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Introduction
Mevalonate kinase deficiency (MKD) is a rare autoin-
flammatory syndrome, characterized by febrile episodes
and generalized inflammation.
Objectives
This study aims to describe the genetic and phenotypic
characteristics of MKD in a large international patient
cohort.
Methods
Patients were enrolled in the Eurofever registry (EAHC
Project No. 2007332), a registry that retrospectively col-
lects information on patients suffering from periodic
fever. An expert on MKD validated all patients on clinical
and genetic criteria.
Results
One hundred and fourteen patients (53 male, 61 female)
with two MVK mutations were included in this study. The
median age of onset was 0.5 years. The median follow up
period was 11.5 years. The majority of the patients were
Caucasian (90%). Ninety-six patients harboured at least
one V377I mutation, fourteen of them had a homozygous
V377I mutation. The second most frequent mutation was
I268T occurring in 29 patients.
Ninety-nine of 114 patients had recurrent inflammatory
episodes, while six patients suffered from a chronic course
and nine patients had a chronic course with exacerbations.
The median disease duration was five days. The median
frequency was 12 per year. Triggers inducing febrile epi-
sodes were mentioned in 108 patients, the most important
ones were vaccination (n=39), infection (n=18) and stress
(n=26).
One hundred and twelve patients suffered from gastro-
intestinal complaints, most of them suffering from vomit-
ing (69%), diarrhoea (84%) and abdominal pain (88%).
Ninety-nine patients also experienced mucocutaneous
symptoms, mainly pharyngitis (28%), stomatitis (60%) and
maculopapular rash (39%). Seventy-one percent of all
patients had arthralgia and 57 percent had myalgia. Arthri-
tis was less common and occurred in 28%. Neurological
complaints occurred in 46 patients, most of them suffering
from headache (38%). Cerebellar syndrome (3%), mental
retardation (4%) and seizures (5%) were noted in some
patients. Many patients had constitutional symptoms, such
as malaise (65%), weight loss (66%), fatigue (63%) and
mood disorders (24%). AA-amyloidosis was noted in six
patients. One patient suffered from macrophage activation
syndrome, a life-threatening complication characterized by
high fever, pancytopenia and liver damage.
Abnormal IgD levels were observed in 55 of 76 tested
patients, while 37 of 40 tested patients showed elevated
urinary mevalonic acid excretions. Inflammatory para-
meters, such as erythrocyte sedimentation rates (98%),
C-reactive protein (94%) and white blood count (66%),
were abnormal in many patients.
Conclusion
This study describes the clinical and genetic characteristics
of 114 MKD patients, which is the largest cohort so far.
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